Publications in collaboration with researchers from Hospital Universitario La Fe (36)

2024

  1. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation

2021

  1. Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study (Leukemia, (2020), 34, 9, (2333-2341), 10.1038/s41375-020-0758-4)

    Leukemia

2020

  1. Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169

  2. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study

    Leukemia, Vol. 34, Núm. 9, pp. 2333-2341

2019

  1. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

    Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035

  2. Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry

    Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732

2018

  1. Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH)

    Transfusion Medicine Reviews, Vol. 32, Núm. 3, pp. 179-185

  2. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

    Leukemia, Vol. 32, Núm. 1, pp. 21-29

2016

  1. Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

    Bone Marrow Transplantation, Vol. 51, Núm. 7, pp. 961-966

2015

  1. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

    Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356

  2. Outcome of graft failure after allogeneic stem cell transplant: Study of 89 patients

    Leukemia and Lymphoma, Vol. 56, Núm. 3, pp. 656-662

2013

  1. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome

    Leukemia Research, Vol. 37, Núm. 7, pp. 769-776

  2. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

    Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922

  3. Tratamiento de infecciones fúngicas en pacientes hematológicos de alto riesgo. La respuesta de AmBisome no se modifica con el uso previo de azoles de amplio espectro

    Revista Espanola de Quimioterapia, Vol. 26, Núm. 1, pp. 64-69

2011

  1. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

    Blood, Vol. 117, Núm. 6, pp. 1799-1805

  2. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

    Expert Review of Hematology, Vol. 4, Núm. 1, pp. 9-16

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

  2. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

    Blood, Vol. 116, Núm. 25, pp. 5650-5659

  3. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome

    Blood, Vol. 115, Núm. 25, pp. 5137-5146

2009

  1. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

    Haematologica, Vol. 94, Núm. 9, pp. 1242-1249